Literature DB >> 1616867

Preventive Pap-smears: balancing costs, risks and benefits.

M van Ballegooijen1, J D Habbema, G J van Oortmarssen, M A Koopmanschap, J T Lubbe, H M van Agt.   

Abstract

The pattern of spontaneous screening for cervical cancer by general practitioners and gynaecologists in The Netherlands is compared with an efficient screening policy resulting from a cost-effective study. Spontaneous screening tends to start and stop too early in a woman's life, and leaves too many women overscreened or unprotected. The combination in young age of a low incidence of invasive cancer and a high incidence of regressive lesions explains relative ineffectiveness and harmfulness of present screening practice. When screening would take place between ages 30 and at least 60, with intervals of about 5 years, as many lives could be saved for half the costs and with only 60% of the unnecessary referrals and treatments. Much attention should be paid to the coverage of the target population. Therapeutic follow-up policies for dysplastic lesions should be restrained.

Entities:  

Mesh:

Year:  1992        PMID: 1616867      PMCID: PMC1977773          DOI: 10.1038/bjc.1992.195

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

1.  Changes in surgical treatments: the example of hysterectomy versus conization for cervical carcinoma in situ.

Authors:  J S Goodwin; W C Hunt; C R Key; J M Samet
Journal:  J Clin Epidemiol       Date:  1990       Impact factor: 6.437

Review 2.  Screening for cancer of the cervix in elderly women.

Authors:  A Fletcher
Journal:  Lancet       Date:  1990-01-13       Impact factor: 79.321

3.  Diagnostic and treatment procedures induced by cervical cancer screening.

Authors:  M van Ballegooijen; M A Koopmanschap; G J van Oortmarssen; J D Habbema; K T Lubbe; H M van Agt
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

Review 4.  Screening for cervical cancer.

Authors:  D M Eddy
Journal:  Ann Intern Med       Date:  1990-08-01       Impact factor: 25.391

5.  An evaluation of screening policies for cervical cancer in England and Wales using a computer simulation model.

Authors:  D M Parkin; S M Moss
Journal:  J Epidemiol Community Health       Date:  1986-06       Impact factor: 3.710

6.  Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes.

Authors:  E Lăără; N E Day; M Hakama
Journal:  Lancet       Date:  1987-05-30       Impact factor: 79.321

7.  Model building on the basis of Dutch cervical cancer screening data.

Authors:  J D Habbema; G J van Oortmarssen; J T Lubbe; P J van der Maas
Journal:  Maturitas       Date:  1985-05       Impact factor: 4.342

8.  The effect of screening on the incidence and mortality of cervical cancer in Finland.

Authors:  T Hakulinen; M Hakama
Journal:  Nowotwory       Date:  1985 Oct-Dec

9.  Effect of cervical cancer screening in Scandinavia.

Authors:  N E Day
Journal:  Obstet Gynecol       Date:  1984-05       Impact factor: 7.661

10.  Effect of population screening for carcinoma of the uterine cervix in Finland.

Authors:  M Hakama
Journal:  Maturitas       Date:  1985-05       Impact factor: 4.342

View more
  4 in total

1.  The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis.

Authors:  M J Al; B C Michel; F F Rutten
Journal:  Pharmacoeconomics       Date:  1996-08       Impact factor: 4.981

Review 2.  Cost-effective policies for cervical cancer screening. An international review.

Authors:  M C Fahs; S B Plichta; J S Mandelblatt
Journal:  Pharmacoeconomics       Date:  1996-03       Impact factor: 4.981

3.  PCR based high risk HPV testing is superior to neural network based screening for predicting incident CIN III in women with normal cytology and borderline changes.

Authors:  L Rozendaal; J Westerga; J C van der Linden; J M Walboomers; F J Voorhorst; E K Risse; M E Boon; C J Meijer
Journal:  J Clin Pathol       Date:  2000-08       Impact factor: 3.411

4.  Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the (cost-)effectiveness.

Authors:  M van Ballegooijen; M E van den Akker-van Marle; P G Warmerdam; C J Meijer; J M Walboomers; J D Habbema
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.